Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
J Appl Clin Med Phys. 2020 Sep;21(9):33-38. doi: 10.1002/acm2.12962. Epub 2020 Jul 2.
To evaluate the dosimetric effects of the AeroForm (AirXanpders®, Palo Alto, CA) tissue expander in-situ for breast cancer patients receiving post-mastectomy radiation therapy.
A film phantom (P1) was constructed by placing the metallic canister of the AeroForm on a solid water phantom with EBT3 films at five depths ranging from 2.6 mm to 66.2 mm. A breast phantom (P2), a three-dimensional printed tissue-equivalent breast with fully expanded AeroForm in-situ, was placed on a thorax phantom. A total of 21 optical luminescent dosimeters (OLSDs) were placed on the anterior skin-gas interface and the posterior chest wall-metal interface of the AeroForm. Both phantoms were imaged with a 16-bit computed tomography scanner with orthopedic metal artifact reduction. P1 was irradiated with an open field utilizing 6 MV and 15 MV photon beams at 0°, 90°, and 270°. P2 was irradiated using a volumetric modulated arc therapy plan with a 6 MV photon beam and a tangential plan with a 15 MV photon beam. All doses were calculated using Eclipse (Varian, Palo Alto, CA) with AAA and AcurosXB (AXB) algorithms.
The average dose differences between film measurements and AXB in the region adjacent to the canister in P1 were within 3.1% for 15 MV and 0.9% for 6 MV. Local dose differences over 10% were also observed. In the chest wall region of P2, the median dose of OLSDs in percentage of prescription dose were 108.4% (range 95.4%-113.0%) for the 15MV tangential plan and 110.4% (range 99.1%-113.8%) for the 6MV volumetric modulated arc therapy plan. In the skin-gas interface, the median dose of the OLSDs were 102.3% (range 92.7%-107.7%) for the 15 MV plan and 108.2% (range 97.8-113.5%) for the 6 MV plan. Measured doses were, in general, higher than calculated doses with AXB calculations. The AAA dose algorithms produced results with slightly larger discrepancies between measurements compared with AXB.
The AeroForm creates significant dose uncertainties in the chest wall-metal interface. The AcurosXB dose calculation algorithm is recommended for more accurate calculations. If possible, post-mastectomy radiation therapy should be delivered after the permanent implant is in place.
评估在接受乳房切除术后放射治疗的乳腺癌患者中,AeroForm(AirXanpders®,Palo Alto,CA)组织扩张器原位的剂量学效应。
通过将 AeroForm 的金属罐放置在固体水模体上,并在五个深度(从 2.6mm 到 66.2mm)处放置 EBT3 胶片,构建胶片模体(P1)。将一个三维打印的组织等效乳房(完全扩张的 AeroForm 原位)放置在胸腔模体上。总共在 AeroForm 的前侧皮肤-气界面和后侧胸壁-金属界面上放置了 21 个光学发光剂量计(OLSD)。使用具有矫形金属伪影减少功能的 16 位计算机断层扫描扫描仪对 P1 和 P2 进行成像。使用 6MV 和 15MV 光子束在 0°、90°和 270°下利用开放野照射 P1。使用 6MV 光子束的容积调制弧形治疗计划和 15MV 光子束的切线计划照射 P2。使用 Eclipse(Varian,Palo Alto,CA)的 AAA 和 AcurosXB(AXB)算法计算所有剂量。
在 P1 中紧邻罐的区域,胶片测量值与 AXB 的平均剂量差异在 15MV 时为 3.1%,在 6MV 时为 0.9%。也观察到局部剂量差异超过 10%。在 P2 的胸壁区域,15MV 切线计划中 OLSD 剂量中位数为处方剂量的 108.4%(范围为 95.4%-113.0%),6MV 容积调制弧形治疗计划中为 110.4%(范围为 99.1%-113.8%)。在皮肤-气界面,15MV 计划中 OLSD 的剂量中位数为 102.3%(范围为 92.7%-107.7%),6MV 计划中为 108.2%(范围为 97.8%-113.5%)。一般来说,测量的剂量高于 AXB 计算的剂量。AAA 剂量算法产生的结果与 AXB 相比,测量值之间的差异略大。
AeroForm 在胸壁-金属界面产生显著的剂量不确定性。推荐使用 AcurosXB 剂量计算算法进行更准确的计算。如果可能,乳房切除术后放射治疗应在永久性植入物就位后进行。